People: DelMar Pharmaceuticals Inc (DMPI.OQ)
Mr. Saiid Zarrabian is President, Chief Executive Officer, Director of the Company. Mr. Zarrabian has served as our Interim President since January 1, 2018, our Interim Chief Executive Officer since November 3, 2017 and has served as a director since July 7, 2017. Since October 2016, Mr. Zarrabian has served as an advisor to Redline Capital Partners, S.A., a Luxemburg based investment firm. From 2012 to 2014 he served as Chairman and member of the Board of La Jolla Pharmaceutical Company during which time the company transitioned from an OTC listed company to a NASDAQ listed company. From 2012 to 2013 he served as President of the Protein Production Division of Intrexon Corporation, a synthetic biology company. He has also previously served as CEO and member of the Board of Cyntellect, Inc., a stem cell processing and visualization Instrumentation company until its sale in 2012, as President and COO of Senomyx, Inc., a company focused on discovery and commercialization of new flavor ingredients, and as COO of Pharmacopeia, Inc., a former publicly-traded provider of combinatorial chemistry discovery services and compounds, where he also served as President & COO of its MSI Division. In addition, Mr. Zarrabian has served on numerous private and public company boards, including at Immune Therapeutics, Inc., Exemplar Pharma, LLC, Ambit Biosciences Corporation, eMolecules, Inc., and Penwest Pharmaceuticals CO. His other experience includes COO at Molecular Simulations, COO of Symbolics, Inc., and as R&D Director at Computervision, Inc. Mr. Zarrabian’s scientific and business executive knowledge, and experience as our interim chief executive officer qualify him to serve on our Board of Directors.
|Total Annual Compensation,||--|
|Restricted Stock Award,||--|
|Long-Term Incentive Plans,||--|
|Fiscal Year Total,||--|